This article is more than 5 years old. Information may no longer be current.
Allergan pharma sales up 16% in fourth quarter of 2004
Click Here to Manage Email Alerts
IRVINE, Calif. — Allergan posted net sales of $556.2 million during the fourth quarter of 2004, with pharmaceutical sales increasing 16.2% over the fourth quarter of 2003, the company announced in a press release.
For the year, the company posted sales of $1.95 billion, of which eye care pharmaceuticals accounted for $1.14 billion. The company’s older glaucoma drugs slid $18 million in sales from 2003 levels, while sales of newer drugs increased $52 million over 2003, and sales of the company’s dry eye treatment increased by $62 million.
Eye care pharmaceuticals accounted for most of the company’s sales in the fourth quarter, at $302 million, up from $272.4 million in the fourth quarter of 2003, the company reported. Botox (botulinum toxin type A) and other neuromodulator drugs accounted for $202.9 million in sales during the fourth quarter of 2004. Glaucoma drugs Alphagan P (brimonidine tartrate 0.15%) and Alphagan (brimonidine tartrate 0.2%) and Combigan (brimonidine tartrate, timolol maleate) posted sales of $63.9 million, down from $73.2 million in the same quarter of 2003. Sales of Lumigan (bimatoprost), another glaucoma drug, increased to $61.8 million from $51.7 million in the year-ago quarter, according to the release.
Dry eye treatment Restasis (cyclosporine) more than doubled its sales from the fourth quarter of 2003, to $34.3 million, up from $15.9 million.